Daraxonrasib Doubles Pancreatic Cancer Survival to 13 Months as FDA Opens Expanded Access
Updated
Updated · Chicago Sun-Times · May 26
Daraxonrasib Doubles Pancreatic Cancer Survival to 13 Months as FDA Opens Expanded Access
3 articles · Updated · Chicago Sun-Times · May 26
13 months of average survival for previously treated metastatic pancreatic cancer patients was reported for daraxonrasib, versus 6 months with standard chemotherapy, in data presented at the ASCO meeting.
The pill targets the KRAS mutation found in more than 90% of pancreatic cancers, making it the first treatment to substantially extend survival in one of the deadliest cancers.
FDA recently allowed expanded access for some eligible patients while Revolution Medicines seeks full approval, which University of Chicago oncologist Ardaman Shergill expects by late summer or fall.
Megan Chung, 55, entered the trial after her cancer returned and said the drug's side effects were far easier than chemotherapy, helping her gain roughly another year with her family.
More than 50,000 people in the U.S. are expected to die of pancreatic cancer this year, underscoring why researchers and patients see daraxonrasib as a potential turning point.
A new drug doubles survival for a deadly cancer, but who are the patients it still cannot save?
This revolutionary cancer pill offers priceless time, but what will be its ultimate cost for patients and insurers?
Daraxonrasib’s Dramatic Impact: Doubling Survival in Metastatic Pancreatic Cancer and Redefining RAS-Targeted Therapy
Overview
Pancreatic cancer is one of the deadliest cancers, with very few patients surviving five years after diagnosis, highlighting an urgent need for better treatments. Daraxonrasib has emerged as a major breakthrough, offering new hope by specifically targeting the KRAS gene, which is mutated in over 90% of pancreatic cancers. This targeted RAS(ON) inhibitor works through a unique mechanism and is also relevant for other cancers like colorectal and lung cancer. The development of daraxonrasib marks a significant step forward, as it addresses a critical gap in treatment and demonstrates the potential of targeting previously 'undruggable' cancer mutations.